Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065182 | 0.87 | KAT2B (0.51) | MAPTHTTALDH1A1HSD17B10TAAR1 | |
| SCHEMBL5840221 | 0.85 | MAPT (0.54) | CA7CA9MAPTHTTALDH1A1 | |
| SCHEMBL5838710 | 0.81 | MAPT (0.44) | MAPTHTTALDH1A1TSHRKAT2B | |
| SCHEMBL5840516 | 0.81 | MAPT (0.44) | CA7CA9MAPTHTTALDH1A1 | |
| SCHEMBL18183961 | 0.80 | GABRA1 (0.42) | CA12CA3CA4CA6CA5A | |
| SCHEMBL5839061 | 0.79 | CHRM2 (0.44) | MAPTHTTALDH1A1KAT2BCYP1A2 | |
| SCHEMBL814598 | 0.79 | MAPT (0.48) | CA7CA9MAPTHTTALDH1A1 | |
| SCHEMBL8013925 | 0.79 | MAPT (0.43) | MAPTHTTALDH1A1CYP1A2IDO1 | |
| SCHEMBL13917945 | 0.77 | RAPGEF4 (0.48) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8521042 | 0.77 | MAPT (0.41) | MAPTHTTALDH1A1KAT2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-115043868-A | Five-membered cyclic aminosilane external electron donor, preparation method and application thereof | 中国科学院化学研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-110330459-B | Carboxylate ionic liquid and preparation method and application thereof | 中国科学院过程工程研究所 | 2022-07-08 | — | — | CN | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3083048-B1 | METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| US-4922021-A | ANTIARRHYTHMIA AGENTS | BASF AKTIENSELLSCHAFT (DE) | 1990-05-01 | — | — | US | disclosed |
| US-4721717-A | α-(aminoalkylaminomethyl)phenylmethanols, composition containing them, and use thereof to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-26 | — | — | US | disclosed |
| US-4608383-A | Cardioactive pyrazole and imidazole aryloxypropanolamines | BOEHRINGER MANNHEIM GMBH (DE) | 1986-08-26 | — | — | US | disclosed |
| EP-0171689-A1 | Aminoalcohols, process for their preparation and medicaments containing these compounds and intermediates | Roche Diagnostics GmbH (DE) | 1986-02-19 | — | — | EP | disclosed |
| EP-0042593-B1 | ARYLOXY-PROPANOL AMINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1985-04-03 | — | — | EP | disclosed |
| US-4479962-A | CARDIOTONIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-10-30 | — | — | US | disclosed |
| US-4438128-A | ADRENERGIC BLOCKERS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | disclosed |
| EP-0071950-A1 | Heteroarylpropanol amines, process for preparing them and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4356322-A | ADRENERGIC STIMULANTS; CARDIOTONIC AGENTS | VEB ARZNEIMITTELWERK DRESDEN (DD) | 1982-10-26 | — | — | US | disclosed |
| EP-0042593-A1 | Aryloxy-propanol amines, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | CA12 2700/4885CA3 1128/4885CA4 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.